Victoria A. Hamilton BHSc*c1, Andrea L.O. Hebb MSc, PhD, RN2*
1 University of Ottawa (Health Sciences), Ottawa, Ontario, Canada
2Dalhousie University (Department of Surgery); Saint Mary’s University (Department of Psychology), Halifax, Nova Scotia, Canada
*Corresponding author: Andrea L.O. Hebb, MSc, PhD, RN, Dalhousie University (Department of Surgery); Saint Mary’s University (Department of Psychology), Halifax, Nova Scotia, Canada, E-mail: [email protected]
Received Date: January 04, 2021
Publication Date: February 18, 2021
Erythropoietin (EPO) is a neuroprotective chemical that is produced by the brain in response to stroke-induced hypoxia. Stroke was first described by Hippocrates (460-377 BC) as apoplexy, the Greek term for “struck down by violence”. In modern day, the term “brain attack” and the expression “time is brain” have been put forward to emphasize the urgency for medical treatment if a stroke is suspected. Stroke assessment and stroke treatment focus on neuroprotective mechanisms to minimize irreversible brain tissue loss. The following discussion will review scientific evidence for the efficacy of EPO in patients with subacute ischemic or hemorrhagic stroke.
KEYWORDS: Stroke; Neuroprotection; Brain attack; Haemorrhage